POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Clinical trials for POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for blood cancer patients battling severe anemia
Disease control OngoingThis study is testing a new drug called INCB000928 to see if it can safely treat severe anemia in people with myelofibrosis, a type of bone marrow cancer. The drug will be given either by itself or in combination with an existing medication, ruxolitinib. The main goals are to see…
Matched conditions: POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New hope for blood cancer patients: Two-Drug combo aims to tame disease
Disease control OngoingThis large, late-stage trial is testing whether adding a new drug called pelabresib to the standard treatment (ruxolitinib) works better for people newly diagnosed with myelofibrosis, a serious bone marrow cancer. The study will see if the combination shrinks enlarged spleens mor…
Matched conditions: POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC